Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas.

Orth MF, Buecklein VL, Kampmann E, Subklewe M, Noessner E, Cidre-Aranaz F, Romero-Pérez L, Wehweck FS, Lindner L, Issels R, Kirchner T, Altendorf-Hofmann A, Grünewald TGP, Knösel T.

Cancer Immunol Immunother. 2020 Mar 28. doi: 10.1007/s00262-020-02552-5. [Epub ahead of print]

PMID:
32222780
2.

Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma - a case report.

Issels RD, Lindner LH, von Bergwelt-Baildon M, Lang P, Rischpler C, Diem H, Mosetter B, Eckl J, Schendel DJ, Salat C, Stötzer O, Burdach S, von Luettichau-Teichert I, Handgretinger R, Neumann J, Kirchner T, Steiger K, Boxberg M, Mansmann U, Multhoff G, Noessner E.

Int J Hyperthermia. 2020;37(1):55-65. doi: 10.1080/02656736.2019.1709666.

PMID:
31918587
3.

Collagen density regulates the activity of tumor-infiltrating T cells.

Kuczek DE, Larsen AMH, Thorseth ML, Carretta M, Kalvisa A, Siersbæk MS, Simões AMC, Roslind A, Engelholm LH, Noessner E, Donia M, Svane IM, Straten PT, Grøntved L, Madsen DH.

J Immunother Cancer. 2019 Mar 12;7(1):68. doi: 10.1186/s40425-019-0556-6.

4.

Roquin Suppresses the PI3K-mTOR Signaling Pathway to Inhibit T Helper Cell Differentiation and Conversion of Treg to Tfr Cells.

Essig K, Hu D, Guimaraes JC, Alterauge D, Edelmann S, Raj T, Kranich J, Behrens G, Heiseke A, Floess S, Klein J, Maiser A, Marschall S, Hrabĕ de Angelis M, Leonhardt H, Calkhoven CF, Noessner E, Brocker T, Huehn J, Krug AB, Zavolan M, Baumjohann D, Heissmeyer V.

Immunity. 2017 Dec 19;47(6):1067-1082.e12. doi: 10.1016/j.immuni.2017.11.008. Epub 2017 Dec 12.

5.

Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.

Schlenker R, Olguín-Contreras LF, Leisegang M, Schnappinger J, Disovic A, Rühland S, Nelson PJ, Leonhardt H, Harz H, Wilde S, Schendel DJ, Uckert W, Willimsky G, Noessner E.

Cancer Res. 2017 Jul 1;77(13):3577-3590. doi: 10.1158/0008-5472.CAN-16-1922. Epub 2017 May 22.

6.

Pulmonary microRNA profiles identify involvement of Creb1 and Sec14l3 in bronchial epithelial changes in allergic asthma.

Bartel S, Schulz N, Alessandrini F, Schamberger AC, Pagel P, Theis FJ, Milger K, Noessner E, Stick SM, Kicic A, Eickelberg O, Freishtat RJ, Krauss-Etschmann S.

Sci Rep. 2017 Apr 6;7:46026. doi: 10.1038/srep46026.

7.

DGK-α: A Checkpoint in Cancer-Mediated Immuno-Inhibition and Target for Immunotherapy.

Noessner E.

Front Cell Dev Biol. 2017 Mar 3;5:16. doi: 10.3389/fcell.2017.00016. eCollection 2017.

8.

A vector platform for the rapid and efficient engineering of stable complex transgenes.

Jäckel C, Nogueira MS, Ehni N, Kraus C, Ranke J, Dohmann M, Noessner E, Nelson PJ.

Sci Rep. 2016 Oct 3;6:34365. doi: 10.1038/srep34365.

9.

Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.

Bücklein V, Adunka T, Mendler AN, Issels R, Subklewe M, Schmollinger JC, Noessner E.

Oncoimmunology. 2016 Apr 29;5(7):e1178421. doi: 10.1080/2162402X.2016.1178421. eCollection 2016 Jul.

10.

A novel role of MMP-13 for murine DC function: its inhibition dampens T-cell activation.

Bartmann J, Frankenberger M, Neurohr C, Eickelberg O, Noessner E, von Wulffen W.

Int Immunol. 2016 Oct;28(10):473-487. Epub 2016 Feb 26.

PMID:
26921214
11.

Impairment of Immunoproteasome Function by Cigarette Smoke and in Chronic Obstructive Pulmonary Disease.

Kammerl IE, Dann A, Mossina A, Brech D, Lukas C, Vosyka O, Nathan P, Conlon TM, Wagner DE, Overkleeft HS, Prasse A, Rosas IO, Straub T, Krauss-Etschmann S, Königshoff M, Preissler G, Winter H, Lindner M, Hatz R, Behr J, Heinzelmann K, Yildirim AÖ, Noessner E, Eickelberg O, Meiners S.

Am J Respir Crit Care Med. 2016 Jun 1;193(11):1230-41. doi: 10.1164/rccm.201506-1122OC.

PMID:
26756824
12.

Podoplanin increases migration and angiogenesis in malignant glioma.

Grau SJ, Trillsch F, Tonn JC, Goldbrunner RH, Noessner E, Nelson PJ, von Luettichau I.

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8663-70. eCollection 2015.

13.

Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis.

Toma M, Wehner R, Kloß A, Hübner L, Fodelianaki G, Erdmann K, Füssel S, Zastrow S, Meinhardt M, Seliger B, Brech D, Noessner E, Tonn T, Schäkel K, Bornhäuser M, Bachmann MP, Wirth MP, Baretton G, Schmitz M.

Oncoimmunology. 2015 Mar 2;4(6):e1008342. eCollection 2015 Jun.

14.

Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.

Bauer C, Hees C, Sterzik A, Bauernfeind F, Mak'Anyengo R, Duewell P, Lehr HA, Noessner E, Wank R, Trauzold A, Endres S, Dauer M, Schnurr M.

J Immunother. 2015 Apr;38(3):116-26. doi: 10.1097/CJI.0000000000000073.

PMID:
25751501
15.

Alterations of costimulatory molecules and instructive cytokines expressed by dendritic cells in the microenvironment of an endogenous mouse lymphoma.

Naujoks M, Weiß J, Riedel T, Hömberg N, Przewoznik M, Noessner E, Röcken M, Mocikat R.

Cancer Immunol Immunother. 2014 May;63(5):491-9. doi: 10.1007/s00262-014-1538-7. Epub 2014 Mar 18.

PMID:
24638151
16.

NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention.

Prinz PU, Mendler AN, Brech D, Masouris I, Oberneder R, Noessner E.

Int J Cancer. 2014 Oct 15;135(8):1832-41. doi: 10.1002/ijc.28837. Epub 2014 Mar 26.

17.

A novel CXCL10-based GPI-anchored fusion protein as adjuvant in NK-based tumor therapy.

Muenchmeier N, Boecker S, Bankel L, Hinz L, Rieth N, Lapa C, Mendler AN, Noessner E, Mocikat R, Nelson PJ.

PLoS One. 2013 Aug 30;8(8):e72749. doi: 10.1371/journal.pone.0072749. eCollection 2013.

18.

Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma.

Noessner E, Brech D, Mendler AN, Masouris I, Schlenker R, Prinz PU.

Oncoimmunology. 2012 Nov 1;1(8):1451-1453.

19.

Treatment of dermal fibroblasts with GPI-anchored human TIMP-1 protein moderates processes linked to scar formation.

Djafarzadeh R, Notohamiprodjo S, Rieth N, Hofstetter M, Noessner E, Nelson PJ.

J Invest Dermatol. 2013 Mar;133(3):803-811. doi: 10.1038/jid.2012.375. Epub 2012 Oct 25.

20.

Uromodulin triggers IL-1β-dependent innate immunity via the NLRP3 inflammasome.

Darisipudi MN, Thomasova D, Mulay SR, Brech D, Noessner E, Liapis H, Anders HJ.

J Am Soc Nephrol. 2012 Nov;23(11):1783-9. doi: 10.1681/ASN.2012040338. Epub 2012 Sep 20.

21.

Binding of the heterogeneous ribonucleoprotein K (hnRNP K) to the Epstein-Barr virus nuclear antigen 2 (EBNA2) enhances viral LMP2A expression.

Gross H, Hennard C, Masouris I, Cassel C, Barth S, Stober-Grässer U, Mamiani A, Moritz B, Ostareck D, Ostareck-Lederer A, Neuenkirchen N, Fischer U, Deng W, Leonhardt H, Noessner E, Kremmer E, Grässer FA.

PLoS One. 2012;7(8):e42106. doi: 10.1371/journal.pone.0042106. Epub 2012 Aug 3.

22.

High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention.

Prinz PU, Mendler AN, Masouris I, Durner L, Oberneder R, Noessner E.

J Immunol. 2012 Jun 15;188(12):5990-6000. doi: 10.4049/jimmunol.1103028. Epub 2012 May 9.

23.

Recombinant GPI-anchored TIMP-1 stimulates growth and migration of peritoneal mesothelial cells.

Djafarzadeh R, Sauter M, Notohamiprodjo S, Noessner E, Goyal P, Siess W, Wörnle M, Ribeiro A, Himmelein S, Sitter T, Nelson PJ.

PLoS One. 2012;7(4):e33963. doi: 10.1371/journal.pone.0033963. Epub 2012 Apr 27.

24.

Modified vaccinia virus Ankara delivers a robust surrogate marker for immune monitoring to sarcoma cells even if cells are being exposed to chemotherapy and heat treatment.

Tschoep-Lechner K, Drexler I, Hammer D, Neumann D, Pohla H, Sutter G, Noessner E, Issels RD.

Int J Hyperthermia. 2012;28(1):33-42. doi: 10.3109/02656736.2011.626834.

PMID:
22235783
25.

Dendritic cells in human renal inflammation--Part II.

Noessner E, Lindenmeyer M, Nelson PJ, Segerer S.

Nephron Exp Nephrol. 2011;119(4):e91-8. doi: 10.1159/000332032. Epub 2011 Nov 4.

26.

Dendritic cells in experimental renal inflammation--Part I.

Lindenmeyer M, Noessner E, Nelson PJ, Segerer S.

Nephron Exp Nephrol. 2011;119(4):e83-90. doi: 10.1159/000332029. Epub 2011 Nov 4. Review.

27.

Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation.

Mendler AN, Hu B, Prinz PU, Kreutz M, Gottfried E, Noessner E.

Int J Cancer. 2012 Aug 1;131(3):633-40. doi: 10.1002/ijc.26410. Epub 2011 Oct 5.

28.

Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging.

Eckl J, Buchner A, Prinz PU, Riesenberg R, Siegert SI, Kammerer R, Nelson PJ, Noessner E.

J Mol Med (Berl). 2012 Jan;90(1):55-66. doi: 10.1007/s00109-011-0806-7. Epub 2011 Aug 26.

PMID:
21870102
29.

The NP9 protein encoded by the human endogenous retrovirus HERV-K(HML-2) negatively regulates gene activation of the Epstein-Barr virus nuclear antigen 2 (EBNA2).

Gross H, Barth S, Pfuhl T, Willnecker V, Spurk A, Gurtsevitch V, Sauter M, Hu B, Noessner E, Mueller-Lantzsch N, Kremmer E, Grässer FA.

Int J Cancer. 2011 Sep 1;129(5):1105-15. doi: 10.1002/ijc.25760. Epub 2011 Jan 12.

30.

Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations.

Figel AM, Brech D, Prinz PU, Lettenmeyer UK, Eckl J, Turqueti-Neves A, Mysliwietz J, Anz D, Rieth N, Muenchmeier N, Buchner A, Porubsky S, Siegert SI, Segerer S, Nelson PJ, Noessner E.

Am J Pathol. 2011 Jul;179(1):436-51. doi: 10.1016/j.ajpath.2011.03.011. Epub 2011 May 18.

31.

Human endogenous retrovirus transcription profiles of the kidney and kidney-derived cell lines.

Haupt S, Tisdale M, Vincendeau M, Clements MA, Gauthier DT, Lance R, Semmes OJ, Turqueti-Neves A, Noessner E, Leib-Mösch C, Greenwood AD.

J Gen Virol. 2011 Oct;92(Pt 10):2356-2366. doi: 10.1099/vir.0.031518-0. Epub 2011 Jun 22.

PMID:
21697344
32.

Hsp70, a messenger from hyperthermia for the immune system.

Jolesch A, Elmer K, Bendz H, Issels RD, Noessner E.

Eur J Cell Biol. 2012 Jan;91(1):48-52. doi: 10.1016/j.ejcb.2011.02.001. Epub 2011 Mar 31. Review.

PMID:
21458102
33.

Cord blood Vα24-Vβ11 natural killer T cells display a Th2-chemokine receptor profile and cytokine responses.

Harner S, Noessner E, Nadas K, Leumann-Runge A, Schiemann M, Faber FL, Heinrich J, Krauss-Etschmann S.

PLoS One. 2011 Jan 31;6(1):e15714. doi: 10.1371/journal.pone.0015714.

34.

T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.

Leisegang M, Turqueti-Neves A, Engels B, Blankenstein T, Schendel DJ, Uckert W, Noessner E.

Clin Cancer Res. 2010 Apr 15;16(8):2333-43. doi: 10.1158/1078-0432.CCR-09-2897. Epub 2010 Apr 6.

35.

Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.

Ebelt K, Babaryka G, Frankenberger B, Stief CG, Eisenmenger W, Kirchner T, Schendel DJ, Noessner E.

Eur J Cancer. 2009 Jun;45(9):1664-72. doi: 10.1016/j.ejca.2009.02.015. Epub 2009 Mar 21.

PMID:
19318244
36.

Interaction of human heat shock protein 70 with tumor-associated peptides.

Pandya MJ, Bendz H, Manzenrieder F, Noessner E, Kessler H, Buchner J, Issels RD.

Biol Chem. 2009 Apr;390(4):305-12. doi: 10.1515/BC.2009.038.

PMID:
19199830
37.

JNK MAPK pathway regulates constitutive transcription of CCL5 by human NK cells through SP1.

Kumar D, Hosse J, von Toerne C, Noessner E, Nelson PJ.

J Immunol. 2009 Jan 15;182(2):1011-20.

38.

Calcium signaling in dendritic cells by human or mycobacterial Hsp70 is caused by contamination and is not required for Hsp70-mediated enhancement of cross-presentation.

Bendz H, Marincek BC, Momburg F, Ellwart JW, Issels RD, Nelson PJ, Noessner E.

J Biol Chem. 2008 Sep 26;283(39):26477-83. doi: 10.1074/jbc.M803310200. Epub 2008 Jul 24.

39.

Differential effects of ifosfamide on dendritic cell-mediated stimulation of T cell interleukin-2 production, natural killer cell cytotoxicity and interferon-gamma production.

Kuppner MC, Bleifuss E, Noessner E, Mocikat R, Hesler Cv, Mayerhofer C, Issels RD.

Clin Exp Immunol. 2008 Sep;153(3):429-38. doi: 10.1111/j.1365-2249.2008.03708.x. Epub 2008 Jul 18.

40.

TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis.

Djafarzadeh R, Milani V, Rieth N, von Luettichau I, Skrablin PS, Hofstetter M, Noessner E, Nelson PJ.

Cancer Immunol Immunother. 2009 Mar;58(3):361-71. doi: 10.1007/s00262-008-0559-5. Epub 2008 Jul 11.

PMID:
18618109
41.

Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.

Bleifuss E, Bendz H, Sirch B, Thompson S, Brandl A, Milani V, Graner MW, Drexler I, Kuppner M, Katsanis E, Noessner E, Issels RD.

Int J Hyperthermia. 2008 Dec;24(8):623-37. doi: 10.1080/02656730802213384.

PMID:
18608582
42.

Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells.

Javorovic M, Wilde S, Zobywalski A, Noessner E, Lennerz V, Wölfel T, Schendel DJ.

J Immunother. 2008 Jan;31(1):52-62.

PMID:
18157012
43.

Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma.

Ebelt K, Babaryka G, Figel AM, Pohla H, Buchner A, Stief CG, Eisenmenger W, Kirchner T, Schendel DJ, Noessner E.

Prostate. 2008 Jan 1;68(1):1-10.

PMID:
17948280
44.

Adoptive transfer of cytotoxic T-cells for treatment of residual disease after irradiation.

Krause M, Schmitz M, Noessner E, Skrablin PS, Wehner R, Rieber EP, Baumann M.

Int J Radiat Biol. 2007 Nov-Dec;83(11-12):827-36.

PMID:
17852560
45.

Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling.

Bendz H, Ruhland SC, Pandya MJ, Hainzl O, Riegelsberger S, Braüchle C, Mayer MP, Buchner J, Issels RD, Noessner E.

J Biol Chem. 2007 Oct 26;282(43):31688-702. Epub 2007 Aug 7.

46.

Immune suppression in renal cell carcinoma.

Frankenberger B, Noessner E, Schendel DJ.

Semin Cancer Biol. 2007 Aug;17(4):330-43. Epub 2007 Jun 23. Review.

PMID:
17656104
47.

Designer T cells by T cell receptor replacement.

Sommermeyer D, Neudorfer J, Weinhold M, Leisegang M, Engels B, Noessner E, Heemskerk MH, Charo J, Schendel DJ, Blankenstein T, Bernhard H, Uckert W.

Eur J Immunol. 2006 Nov;36(11):3052-9.

48.

Expression of the chemokine receptor CXCR1 in human glomerular diseases.

Segerer S, Henger A, Schmid H, Kretzler M, Draganovici D, Brandt U, Noessner E, Nelson PJ, Kerjaschki D, Schlöndorff D, Regele H.

Kidney Int. 2006 May;69(10):1765-73.

49.

Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma.

Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Gröne EF, Hohenfellner M, Haferkamp A, Pohla H, Schendel DJ, Falk CS, Noessner E.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):718-25.

50.

GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing.

Djafarzadeh R, Noessner E, Engelmann H, Schendel DJ, Notohamiprodjo M, von Luettichau I, Nelson PJ.

Oncogene. 2006 Mar 9;25(10):1496-508.

PMID:
16261161

Supplemental Content

Loading ...
Support Center